Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Triplet therapy including androgen deprivation therapy, docetaxel, and darolutamide offers the best overall survival for metastatic hormone-sensitive prostate cancer with visceral disease. Doublet regimens with chemotherapy or abiraterone are also effective options.
Area Of Science
- Oncology
- Clinical Trials
- Systematic Reviews
Background
- Metastatic hormone-sensitive prostate cancer (mHSPC) with visceral disease (VD) is a high-risk group with poor prognosis.
- Optimal systemic therapy for mHSPC with VD remains unclear despite treatment intensification.
- This study focuses on evaluating current therapeutic combinations for mHSPC patients with VD.
Purpose Of The Study
- To evaluate the efficacy of current therapeutic combinations for overall survival (OS) in mHSPC patients with VD.
- To identify the most effective systemic therapy for this high-risk subgroup.
- To compare different treatment regimens including triplet and doublet therapies.
Main Methods
- A systematic review and network meta-analysis (NMA) of Phase 3 randomised controlled trials.
- Included studies reported OS outcomes for mHSPC patients with VD.
- Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and analyzed using a frequentist NMA framework.
Main Results
- Eight trials (7944 patients, 1189 with VD) were included in the NMA.
- Androgen deprivation therapy (ADT) + docetaxel + darolutamide showed the greatest OS benefit (HR = 0.42).
- ADT + docetaxel (HR = 0.53) and ADT + abiraterone (HR = 0.58) were superior doublet regimens compared to others.
Conclusions
- Triplet therapy (ADT + docetaxel + darolutamide) offers the most significant OS benefit for mHSPC patients with VD.
- Doublet regimens with chemotherapy or abiraterone are viable alternatives.
- Further research is needed to personalize treatment based on VD biology and metastatic site.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...